Prelude Capital Management’s Avidity Biosciences RNAM Stock Holding History

Prelude Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-111,919	Closed	-$8.07M	–	1531
2025 Q4	$8.07M	Buy	+111,919	New	+$7.23M	0.59%	25
2024 Q2	–	Sell	-24,654	Closed	-$629K	–	1453
2024 Q1	$629K	Buy	+24,654	New	+$386K	0.03%	534
2023 Q2	–	Sell	-22,240	Closed	-$341K	–	1314
2023 Q1	$341K	Buy	+22,240	New	+$489K	0.02%	599

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

Prelude Capital Management's RNAM Position: Q1 2026 in Review

Prelude Capital Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 111,919 shares — an estimated $8.07M sold.

Prelude Capital Management first reported a position in RNAM in Q1 2023 and held it in 3 quarters. The position peaked at $8.07M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Prelude Capital Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 111,919 Avidity Biosciences shares in Q1 2026, an estimated $8.07M.
Prelude Capital Management first reported a position in Avidity Biosciences in Q1 2023 and held it in 3 quarters.
Prelude Capital Management's Avidity Biosciences position peaked at $8.07M in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.